Relevant conflicts of interest/financial disclosures: Nothing to report.
Version of Record online: 24 MAY 2011
Copyright © 2011 Movement Disorder Society
Volume 26, Issue 11, pages 1997–2003, September 2011
How to Cite
Politis, M., Oertel, W. H., Wu, K., Quinn, N. P., Pogarell, O., Brooks, D. J., Bjorklund, A., Lindvall, O. and Piccini, P. (2011), Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. Mov. Disord., 26: 1997–2003. doi: 10.1002/mds.23743
Full financial disclosures and author roles may be found in the online version of this article.
- Issue online: 19 SEP 2011
- Version of Record online: 24 MAY 2011
- Manuscript Accepted: 15 MAR 2011
- Manuscript Revised: 2 MAR 2011
- Manuscript Received: 22 JAN 2011
- serotonin transporter; dopamine transporter
Graft-induced dyskinesias are a serious complication after neural transplantation in Parkinson's disease. One patient with Parkinson's disease, treated with fetal grafts 14 years ago and deep brain stimulation 6 years ago, showed marked improvement of motor symptoms but continued to suffer from OFF-medication graft-induced dyskinesias. The patient received a series of clinical and imaging assessments. Positron emission tomography and single-photon emission computed tomography 14 years posttransplantation revealed an elevated serotonin/dopamine transporter ratio in the grafted striatum compatible with serotonergic hyperinnervation. Inhibition of serotonin neuron activity by systemic administration of a 5-HT1A agonist suppressed graft-induced dyskinesias. Our data provide further evidence that serotonergic neurons mediate graft-induced dyskinesias in Parkinson's disease. Achieving a normal striatal serotonin/dopamine transporter ratio following transplantation of fetal tissue or stem cells should be necessary to avoid the development of graft-induced dyskinesias. © 2011 Movement Disorder Society